BIOVIE INC. - COMMON STOCK

BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

06 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

02 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BioVie Announces “BioVie Day” to be held March 23, 2023

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

07 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

06 Dec 2022 05:00:00 By Nasdaq GlobeNewswire

BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

05 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients

29 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

15 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

24 Oct 2022 07:00:03 By Nasdaq GlobeNewswire

BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

19 Oct 2022 05:00:00 By Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

04 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference

29 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

07 Sep 2022 05:00:00 By Nasdaq GlobeNewswire

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

23 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference

25 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

10 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

09 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

20 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

28 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

BioVie Announces Partnership with the American Liver Foundation

09 Dec 2021 07:00:01 By Nasdaq GlobeNewswire